Clinical Trials
View the National Cancer Institute's "Understanding Cancer Clinical Trials" video. 
Read "On the Cutting Edge: Patients in Clinical Trials of New Drugs Must Weigh Risk vs Reward" from the November issue of New Jersey Monthly magazine.
Listen to the American Society of Clinical Oncologists' podcast entitled, "What are Clinical Trials."
Clinical research touches every person’s life on a regular basis. It plays an important role in moving medical science and improving the public’s health. According to the U.S. Census Bureau, more than half of all Americans are taking prescription medications at the present time. Most Americans report routinely using over-the-counter medications. All medicines, both prescription and over-the-counter, have gone through clinical testing, involving people who have volunteered to take part in a clinical trial, also known as a research study. All of today’s successful treatments for cancer are based on results of past clinical trials. Because of progress made through clinical trials, people treated for cancer are living longer.
As one of the National Cancer Institute’s designated cancer centers, The Cancer Institute of New Jersey is able to provide access to clinical trials not available at other hospitals, clinics or doctor’s offices. The Cancer Institute of New Jersey currently enrolls more than 1,000 patients in clinical trials or approximately 15% of all its new adult cancer patients and approximately 70% of all pediatric cancer patients on clinical trials. The Cancer Institute of New Jersey is committed to finding the latest and best treatment options for cancer patients through clinical trials.
For additional information about clinical trials at CINJ contact us at 732-235-8675 or cinjclinicaltrials@umdnj.edu or find a clinical trial at CINJ.
Recent News About Clinical Trials
Clinical Trial Looks to Harness Body’s Own Immune System to Tackle Pancreatic Cancer
It has been known for a number of years based on studies by scientists at CINJ and elsewhere, that the presence of a tumor in the body can actively inhibit the immune system from recognizing and destroying these same tumors. Studies at CINJ have shown this blockade of immunity also prevents traditional cancer vaccines from producing a good response. As part of these studies at CINJ, investigators have shown that injecting a vaccine and other immunity-producing drugs into the tumor itself -- rather than the traditional site of the skin -- can result in a reversal of the immune blockade and the development of specific immunity to the tumor.
Clinical Trial Focuses on New Immune Therapy in Combination with Standard Treatment for Common Form of Kidney Cancer
Researchers at CINJ are evaluating whether the standard treatment for a common form of kidney cancer works better by itself or when combined with a certain type of blood cell that comes from a patient’s relative. The Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients with Renal Cell Carcinoma -- or SPECIAL -- trial is sponsored by the United States Food and Drug Administration, which also will monitor the study.
Breast Cancer Study Seeks Healthy Volunteers
Research currently underway at CINJ and CINJ-Hamilton, which may unlock the mysteries of why some women develop breast cancer at an earlier age than others, has been expanded to include more healthy volunteers than previously sought. Investigators hope to shed light on these figures through an ongoing clinical trial whose goal is to identify genetic markers for the disease. By including larger numbers of healthy women in the study, the researchers hope to pinpoint genetic differences between women who develop breast cancer and those who do not.
|
